Serum Transthyretin as Prognostic Biomarker for Cardiovascular Events and Mortality: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Serum transthyretin (TTR) levels, a key player in the occurrence of amyloidosis, have also emerged as a potential biomarker in cardiovascular (CV) disease and all-cause mortality. However, it is unclear whether TTR levels predict future events.

Objectives

This meta-analysis sought to evaluate the prognostic utility in longitudinal studies of serum TTR levels in predicting CV events, heart failure (HF), CV mortality, and all-cause mortality across diverse patient populations.

Methods

A systematic literature search was conducted across major electronic databases and gray literature up to May 2025. Studies reporting HRs or risk estimates for the association between serum TTR levels and outcomes of interest (CV events and mortality) were included. Two reviewers

SUBMITTER: Terentes-Printzios D 

PROVIDER: S-EPMC12517089 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature